Skip to main content
NewslettersWatchlist

Amgen Inc(AMGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low310.37
Day High315.28
Open:315.28
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Newswire.ca
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
BayStreet.ca
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer
Motley Fool
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
Barchart
Stocks Settle Higher on Solid Earnings and Fed Rate Cut Optimism
Barchart
Stocks Climb on Strength in Chips Stocks and Fed Rate Cut Optimism
Barchart
Stocks Set to Open Higher as Investors Await More Corporate Earnings and Fed Speak
Motley Fool
Why Amgen Stock Zoomed Nearly 12% Higher Today
Barchart
Stocks Close Higher as the Outlook Improves for Fed Rate Cuts
Barchart
Stocks Climb as US Jobs Report Ramps Up Fed Rate Cut Expectations
Baystreet
Markets Show Muscle
Barchart
Stocks Jump on Apple Earnings and Dovish Apr Payroll Report
The Globe and Mail
Market movers: Stocks seeing action on Friday - and why
Barchart
Nasdaq Futures Climb on Upbeat Apple Results, U.S. Jobs Report in Focus
Baystreet
TSX Wobbles at Thursday Open
Barchart
Stocks Climb Before the Open After Fed Decision, Apple Earnings on Tap
Barchart
Options Watchlist: 10 Stocks Showing High IV Percentile
Barchart
Is Amgen Stock a Buy for Its 3% Yield?
Barchart
Stocks Set to Open Higher as Investors Await U.S. Jobs Data and More Big Tech Earnings, Fed Meeting on Tap
Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
Motley Fool
Can This High-Yield Dividend Stock Keep Beating the S&P 500?

Profile

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.